Cargando…
Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice
Protected and specific delivery of nucleic acids to malignant cells remains a highly desirable approach for cancer therapy. Here we present data on the physical and chemical characteristics, mechanism of action, and pilot therapeutic efficacy of a tenfibgen (TBG)-shell nanocapsule technology for tum...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198192/ https://www.ncbi.nlm.nih.gov/pubmed/25333839 http://dx.doi.org/10.1371/journal.pone.0109970 |
_version_ | 1782339707050393600 |
---|---|
author | Trembley, Janeen H. Unger, Gretchen M. Korman, Vicci L. Abedin, Md. Joynal Nacusi, Lucas P. Vogel, Rachel I. Slaton, Joel W. Kren, Betsy T. Ahmed, Khalil |
author_facet | Trembley, Janeen H. Unger, Gretchen M. Korman, Vicci L. Abedin, Md. Joynal Nacusi, Lucas P. Vogel, Rachel I. Slaton, Joel W. Kren, Betsy T. Ahmed, Khalil |
author_sort | Trembley, Janeen H. |
collection | PubMed |
description | Protected and specific delivery of nucleic acids to malignant cells remains a highly desirable approach for cancer therapy. Here we present data on the physical and chemical characteristics, mechanism of action, and pilot therapeutic efficacy of a tenfibgen (TBG)-shell nanocapsule technology for tumor-directed delivery of single stranded DNA/RNA chimeric oligomers targeting CK2αα' to xenograft tumors in mice. The sub-50 nm size TBG nanocapsule (s50-TBG) is a slightly negatively charged, uniform particle of 15 - 20 nm size which confers protection to the nucleic acid cargo. The DNA/RNA chimeric oligomer (RNAi-CK2) functions to decrease CK2αα' expression levels via both siRNA and antisense mechanisms. Systemic delivery of s50-TBG-RNAi-CK2 specifically targets malignant cells, including tumor cells in bone, and at low doses reduces size and CK2-related signals in orthotopic primary and metastatic xenograft prostate cancer tumors. In conclusion, the s50-TBG nanoencapsulation technology together with the chimeric oligomer targeting CK2αα' offer significant promise for systemic treatment of prostate malignancy. |
format | Online Article Text |
id | pubmed-4198192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41981922014-10-21 Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice Trembley, Janeen H. Unger, Gretchen M. Korman, Vicci L. Abedin, Md. Joynal Nacusi, Lucas P. Vogel, Rachel I. Slaton, Joel W. Kren, Betsy T. Ahmed, Khalil PLoS One Research Article Protected and specific delivery of nucleic acids to malignant cells remains a highly desirable approach for cancer therapy. Here we present data on the physical and chemical characteristics, mechanism of action, and pilot therapeutic efficacy of a tenfibgen (TBG)-shell nanocapsule technology for tumor-directed delivery of single stranded DNA/RNA chimeric oligomers targeting CK2αα' to xenograft tumors in mice. The sub-50 nm size TBG nanocapsule (s50-TBG) is a slightly negatively charged, uniform particle of 15 - 20 nm size which confers protection to the nucleic acid cargo. The DNA/RNA chimeric oligomer (RNAi-CK2) functions to decrease CK2αα' expression levels via both siRNA and antisense mechanisms. Systemic delivery of s50-TBG-RNAi-CK2 specifically targets malignant cells, including tumor cells in bone, and at low doses reduces size and CK2-related signals in orthotopic primary and metastatic xenograft prostate cancer tumors. In conclusion, the s50-TBG nanoencapsulation technology together with the chimeric oligomer targeting CK2αα' offer significant promise for systemic treatment of prostate malignancy. Public Library of Science 2014-10-15 /pmc/articles/PMC4198192/ /pubmed/25333839 http://dx.doi.org/10.1371/journal.pone.0109970 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Trembley, Janeen H. Unger, Gretchen M. Korman, Vicci L. Abedin, Md. Joynal Nacusi, Lucas P. Vogel, Rachel I. Slaton, Joel W. Kren, Betsy T. Ahmed, Khalil Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice |
title | Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice |
title_full | Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice |
title_fullStr | Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice |
title_full_unstemmed | Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice |
title_short | Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice |
title_sort | tenfibgen ligand nanoencapsulation delivers bi-functional anti-ck2 rnai oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198192/ https://www.ncbi.nlm.nih.gov/pubmed/25333839 http://dx.doi.org/10.1371/journal.pone.0109970 |
work_keys_str_mv | AT trembleyjaneenh tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT ungergretchenm tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT kormanviccil tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT abedinmdjoynal tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT nacusilucasp tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT vogelracheli tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT slatonjoelw tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT krenbetsyt tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice AT ahmedkhalil tenfibgenligandnanoencapsulationdeliversbifunctionalantick2rnaioligomertokeysitesforprostatecancertargetingusinghumanxenografttumorsinmice |